Curis, Inc. · NASDAQ:CRIS
Curis — Investor Presentation (November 2006)
35 slides from Curis's investor presentation, Nov 14, 2006
Slide 1: Curis, Inc. (NASDAQ: CRIS) Curis Presentation
Curis, Inc. (NASDAQ: CRIS) Curis Presentation November 14, 2006 1
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains statements about Curis’ future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially f
Slide 3: Pipeline
Pipeline Primary Candidate Development Stage Product Licensee Primary Indication Early Mid Late Discovery preclinical preclinical preclinical IND I II III NDA Products Hh systemic small molecule or antibody antagonist Cancer IND Filed Filed October 2006 Hh systemic small molecule agonist Nervous s
Slide 4: Pipeline
Pipeline Primary Candidate Development Stage Product Licensee Primary Indication Early Mid Late Discovery preclinical preclinical preclinical IND I II III NDA Products Hh systemic small molecule or antibody antagonist Curis Cancer believes that partnering has created IND Filed a balanced Filed on 9/
Slide 5: Pipeline
Pipeline Primary Candidate Development Stage Product Licensee Primary Indication Early Mid Late Discovery preclinical preclinical preclinical IND I II III NDA Products Hh systemic small molecule or antibody antagonist Growing Cancer portfolio of proprietary, IND Filed Filed on 9/29/06 Curis-owned
Slide 6: Anticipated Near Term Milestones
Anticipated Near Term Milestones Discovery Validate HTS Medicinal Preclinical IND Clinical Phases Products Target Chem Early Mid Late I II III Initiation Phase I Trial Hh (IND filed Oct. ’06) Multi-Target Oncology A-B4 A– A–B1 Selection of Lead Oncology Program Anticipated 1H’07 A-B5 A– A–B2 Selecti
Slide 7: Novel, Proprietary Multi-Target Oncology Platform
Novel, Proprietary Multi-Target Oncology Platform Discovery Validate HTS Medicinal Preclinical IND Clinical Phases Products Target Chem Early Mid Late I II III Multi-Target A-B4 A– A–B1 Oncology Program A-B5 A– A–B2 A– A–B3 7
Slide 8: Multi-Target Inhibitor Design and Synergy of Drug A
Multi-Target Inhibitor Design and Synergy of Drug A B= CDK MEK Inhibitor Inhibitor Multikinase Inhibitor 1 EGFR Inhibitor Multikinase Inhibitor 2 VEGFR Drug A B Inhibitor Retinoic acid Bcr-Abl Inhibitor Proteasome DNMT Inhibitor Inhibitor Others 8
Slide 9: Rationale for Multi-Target Inhibitors
Rationale for Multi-Target Inhibitors The case for multi-target drugs: Oncology Heterogeneity of cells within tumors Redundancy of proliferative and survival pathways Potential synergies could lead to superior efficacy, which is expected to lead to reduced dosage and toxicity Simultaneous inhibition
Slide 10: Design of A/B Inhibitors
Design of A/B Inhibitors Drug 1 Drug 2 Target A Target B Non-binding Binding Binding Non-binding region group group region Functional Group Functional Group Drug A Drug B A/B Inhibitors Binding Binding group A Group B Functional Group Functional Group Drug A Drug B 10
Slide 11: Upcoming Objectives – Multi-Targeted Oncology Inhibitors
Upcoming Objectives – Multi-Targeted Oncology Inhibitors In Vivo efficacy demonstrating synergistic effects in at least one multi-targeted inhibitor class of compounds; 2H 2006 Lead candidate selection; 1H 2007 IND application filing; 2H 2007 or 1H 2008 11
Slide 12: Potent Dual Inhibitory Activities in in vitro Assays
Potent Dual Inhibitory Activities in in vitro Assays EGFR Assay Target TargetAAAssay Assay A Source: Curis Data 12
Slide 13: Anti-Proliferative Activity of Multi-Target Inhibitors in A431 Cells
Anti-Proliferative Activity of Multi-Target Inhibitors in EGFRi-Sensitive A431 Epidermoidal Carcinoma Cells A Source: Curis Data 13
Slide 14: Apoptotic Effects of Multi-Target Inhibitors on SKBR3 Cells
Apoptotic Effects of Multi-Target Inhibitors on EGFR Inhibitor-Insensitive SKBR3 Breast Cancer cells 3.0 Target A Inhibitor 2.5 Caspase 3/7 (fold change) EGFR Inhibitor CUR MTI-1 CUR MTI-2 2.0 1.5 1.0 0.5 0.001 0.01 0.1 1 10 100 Concentrations (uM) Source: Curis Data 14
Slide 15: Proprietary Drug Platform
Proprietary Drug Platform Multi-Targeting Drug Platform: A-B To fully exploit platform approach, 1 1 2 3 A - B , B ,B … dramatic enhancement in medicinal 2 1 2 3 chemistry capabilities needed A - B , B ,B … 3 1 2 3 A - B , B ,B … 4 1 2 3 Recently established China-based A - B , B ,B … medicinal chem
Slide 16: Curis Model: Core Competencies and Enhanced Capacity (Curis China)
Curis Model: Core Competencies and Enhanced Capacity & Productivity (Curis China) Disco Target Med Preclinical IND Clinical Phases Products Valid HTS Chem Early Mid Late very I II III Back-up #2 Lead Drug Lead Back-up #1 Curis Curis Curis US China US 16
Slide 17: Curis Model: Core Competencies and Enhanced Capacity (Curis China)
Curis Model: Core Competencies and Enhanced Capacity & Productivity (Curis China) Disco Target Med Preclinical IND Clinical Phases Products Valid HTS Chem Early Mid Late very I II III Back-up #2 Lead Drug China operation Lead expected to result in: Back-up #1 • Enhanced Capacity • Decreased Cost • I
Slide 18: Partner-Program Status Update
Partner-Program Status Update Disco Target Med Preclinical IND Clinical Phases Products Valid HTS Chem Early Mid Late very I II III Hh Oncology Hh Neurology Undisclosed Pathway Screens Hair Re- Growth Hh Agonist Screens BMP-7 BMP-7 Small Molecule Screens 18
Slide 19: Partner-Program Status Update
Partner-Program Status Update Disco Target Med Preclinical IND Clinical Phases Products Valid HTS Chem Early Mid Late very I II III Hh Oncology Hh Neurology Undisclosed Pathway Screens Hair Re- Growth Hh Agonist Screens BMP-7 BMP-7 Small Molecule Screens 19
Slide 20: Hedgehog-Associated Cancers
Hedgehog-Associated Cancers Medulloblastoma1 Small Cell Lung Cancer 2 Pancreatic Carcinoma 3,4 Stomach Cancer 4 Esophageal Cancer 4 Colorectal Cancer 5 Prostate Cancer 6,7,8 Breast Cancer 9 1 Romer et al, 2004, 2 Watkins et al, 2003, 3 Thayer et al, 2003, 4 Berman et al, 2003, 5 Qualtrough et al 200
Slide 21: Abnormal Hedgehog Expression Supports Growth of Certain Cancers
Abnormal Hedgehog Expression Supports Growth of Certain Cancers Certain Cancers Small Hedgehog Antibodies Molecules Protein Adjacent Stromal Cells Angiogenesis Factors Growth Factors VEGF, Ang-1, Ang-2 IGF-I,BDNF, NGF 21
Slide 22: Hedgehog Antagonist Intellectual Property Position
Hedgehog Antagonist Intellectual Property Position Filed seminal patents on Hedgehog pathway members, a broad series of small molecules, methods claims, including methods of treating cancer and screening assays, protein, antibody Curis has exclusive license from Johns Hopkins Univ. re: very broad pa
Slide 23: Genentech - Update
Genentech - Update 1st Lead Clinical Hh ant. Drug Candidate Selected by Genentech IND filed October 2006 for 1st Oncology indication Resulted in a $ 3M cash payment to Curis Subsequent clinical development milestones provide further cash payments to Curis Undisclosed Pathway Program in Medicinal
Slide 24: Partner-Program Status Update
Partner-Program Status Update Disco Target Med Preclinical IND Clinical Phases Products Valid HTS Chem Early Mid Late very I II III Hh Oncology Hh Neurology Undisclosed Pathway Screens Hair Re- Growth Hh Agonist Screens BMP-7 BMP-7 Small Molecule Screens 24
Slide 25: Hedgehog Pathway is Activated in Response to Nerve Injury
Hedgehog Pathway is Activated in Response to Nerve Injury BLUE staining Relative Level of Hedgehog mRNA denotes presence of Hedgehog 600 400 Day 0 Day 1 200 0 0 1 3 7 13 Time After Injury (days) Source: internal Curis research 25
Slide 26: Vehicle vs Hh Agonist
Vehicle Hh Agonist Photos of 5 brain slices (2mm)showing the effect of Hh agonist dosing 6 hrs post-MCAO. Slices are organized rostral (top) to caudal (bottom) through the forebrain of a vehicle and Hh agonist (3 mg/kg, iv) rat that were dosed 6 hrs post- MCAO onset. Slices were harvested 48 hrs pos
Slide 27: Wyeth Program Status Hh Agonist
Wyeth Program Status Hh Agonist Lead Clinical Drug Candidate Selection 2007 (cash payment) IND filing approximately 12 months from lead selection (cash payment) Protein being evaluated for systemic cardiovascular Proof of principle preclinical studies ongoing Subject to separate milestone and royalt
Slide 28: Partner-Program Status Update
Partner-Program Status Update Disco Target Med Preclinical IND Clinical Phases Products Valid HTS Chem Early Mid Late very I II III Hh Oncology Hh Neurology Undisclosed Pathway Screens Hair Re- Growth Hh Agonist Screens BMP-7 BMP-7 Small Molecule Screens 28
Slide 29: Hair Growth R&D Agreement with P&G
Hair Growth R&D Agreement with P&G P&G received worldwide exclusive license to Curis’ Hedgehog agonist technology for dermatological indications Potential cash payments of $100 million, in addition to royalties and research support Curis has the option to co-develop candidate from IND filing through
Slide 30: Small Molecule Hedgehog Agonist Promotes Hair Growth
Small Molecule Hedgehog Agonist Promotes Hair Growth Vehicle Treated Agonist Treated One dose, topical application, day 13 after treatment Source: internal Curis research 30
Slide 31: Program Status
Program Status 1st preclinical development objective reached; $1.0 M cash payment received 2nd preclinical development objective based upon lead candidate selection Expected 1H 2007; $1.8M cash payment IND filing anticipated within 12 months of lead selection IND will trigger cash milestone or Cur
Slide 32: Strong Intellectual Property Position
Strong Intellectual Property Position Hundreds of patents issued, allowed or pending in U.S. and abroad Compositions of matter covering signaling proteins, receptors, antibodies, small molecule agonists and antagonists, and others Fields of medical use including renal disorders, metabolic bone disea
Slide 33: Financial Data
Financial Data (amounts in 000’s except per share data) September 30, 2006 Cash, cash equivalents, investments $ 35,200 Accounts receivable $ 3,000 Term debt $ 2,300 Shareholders’ equity $ 34,100 Basic shares outstanding 49,200 Fully diluted shares outstanding 61,600 YTD loss per share $ (0.19) 33
Slide 34: Curis Business Strategy
Curis Business Strategy A Balanced Business Model A portfolio approach to drug development Partnerships with top-tier Pharma provide validation Potential cash milestones under top five deals total ~$750 million in addition to royalties on product sales Diverse collaboration structures balance risk a
Slide 35: Curis, Inc. (NASDAQ: CRIS)
Curis, Inc. (NASDAQ: CRIS) Curis Presentation November 14, 2006 35